IL2 and autoimmune disease: It is worth mentioning that in the clinical data discussed, single doses administered for the treatment of autoimmune disease were about 10–150 times lower than those used in the cancer IL-2 therapy, where cytokine was administered intravenously at doses of 6–7.2 × 105 IU/kg/dose (over 15 min) every 8 h for a maximum of 15 doses, which constitutes about 42–50 × 106 IU per single dose and 630–750 × 106 IU as a cumulative dose (calculations assume mean body weight 70 kg).